|
Gene: KCNAB2 |
Gene summary for KCNAB2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | KCNAB2 | Gene ID | 8514 |
Gene name | potassium voltage-gated channel subfamily A regulatory beta subunit 2 | |
Gene Alias | AKR6A5 | |
Cytomap | 1p36.31 | |
Gene Type | protein-coding | GO ID | GO:0001508 | UniProtAcc | A0A024R4E3 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
8514 | KCNAB2 | HCC2 | Human | Liver | HCC | 7.14e-06 | 3.12e+00 | 0.5341 |
8514 | KCNAB2 | S014 | Human | Liver | HCC | 1.43e-07 | 4.16e-01 | 0.2254 |
8514 | KCNAB2 | S015 | Human | Liver | HCC | 1.70e-07 | 5.72e-01 | 0.2375 |
8514 | KCNAB2 | S016 | Human | Liver | HCC | 6.14e-18 | 7.03e-01 | 0.2243 |
8514 | KCNAB2 | S028 | Human | Liver | HCC | 3.24e-04 | 3.16e-01 | 0.2503 |
8514 | KCNAB2 | S029 | Human | Liver | HCC | 1.49e-09 | 4.44e-01 | 0.2581 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
Tissue | Expression Dynamics | Abbreviation |
Liver | HCC: Hepatocellular carcinoma | |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0006739 | Liver | HCC | NADP metabolic process | 25/7958 | 35/18723 | 5.05e-04 | 3.29e-03 | 25 |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
KCNAB2 | SNV | Missense_Mutation | novel | c.31N>T | p.Arg11Trp | p.R11W | Q13303 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.603) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
KCNAB2 | SNV | Missense_Mutation | novel | c.401N>G | p.Asn134Ser | p.N134S | Q13303 | protein_coding | tolerated(0.28) | benign(0.003) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
KCNAB2 | SNV | Missense_Mutation | novel | c.479N>T | p.Thr160Met | p.T160M | Q13303 | protein_coding | tolerated(0.07) | possibly_damaging(0.723) | TCGA-AX-A1C5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unspecific | Carboplatin | SD |
KCNAB2 | SNV | Missense_Mutation | c.453G>T | p.Lys151Asn | p.K151N | Q13303 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
KCNAB2 | SNV | Missense_Mutation | rs376203067 | c.46N>T | p.Arg16Trp | p.R16W | Q13303 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.689) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
KCNAB2 | SNV | Missense_Mutation | novel | c.1120N>G | p.Asn374Asp | p.N374D | Q13303 | protein_coding | deleterious(0.02) | benign(0.14) | TCGA-EY-A1GU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
KCNAB2 | SNV | Missense_Mutation | rs764251640 | c.574C>T | p.Arg192Cys | p.R192C | Q13303 | protein_coding | deleterious(0.01) | benign(0.281) | TCGA-FI-A2D0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
KCNAB2 | SNV | Missense_Mutation | novel | c.222C>A | p.Asn74Lys | p.N74K | Q13303 | protein_coding | deleterious(0.01) | probably_damaging(0.984) | TCGA-QF-A5YS-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
KCNAB2 | insertion | Frame_Shift_Ins | novel | c.1114dupG | p.Ala372GlyfsTer29 | p.A372Gfs*29 | Q13303 | protein_coding | TCGA-D1-A163-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | taxol | SD | ||
KCNAB2 | SNV | Missense_Mutation | c.391N>A | p.Val131Ile | p.V131I | Q13303 | protein_coding | tolerated(0.42) | benign(0.011) | TCGA-DD-A3A8-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |